Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy
Published on 02/07/2026 at 17:54 | Redaktion boerse-global.de
The integration of Vigil Neuroscience into French pharmaceutical giant Sanofi has been finalized. This strategic move, which concluded in late summer 2025, provides Sanofi with full control over Vigil’s promising neurology pipeline, with a particular focus on advancing a novel Alzheimer’s disease treatment candidate.
Sanofi secured the biotechnology firm through an all-cash transaction. The deal involved a payment of $8.00 per share, valuing the total acquisition at approximately $470 million. The company’s independence formally ended with its delisting from the Nasdaq in August 2025.
Key financial terms for former Vigil shareholders included:
* An upfront cash consideration of $8.00 per share upon deal closure.
* An additional Contingent Value Right (CVR) Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
